GoodRx Holdings Inc. (NASDAQ:GDRX) is considered an oversold stock to buy now. Bank of America analyst Allen Lutz lowered the price target to $2.60 from $3 and maintained an Underperform rating. Morgan Stanley also reduced the price target to $4 with an Equal Weight rating. Barclays initiated coverage with an Underweight rating and $3 price target on December 8. GoodRx offers tools for consumers to compare prescription drug prices in the US.

Read more at Yahoo Finance: BofA Maintains Underperform Rating on GoodRx (GDRX) While Trimming PT to $2.60